Clinical Trials Browser

Has results × Ovarian Neoplasms × nintedanib × Clear all

NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Phase 1 Completed

19 enrolled 21 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01669798 2018-10-16

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Phase 2 Completed

32 enrolled 19 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3 Completed

1,366 enrolled 17 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT00710762 2016-08-15

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

Phase 2 Completed

89 enrolled 10 charts

Ovarian Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Phase 1 Terminated

2 enrolled 5 charts

Ovarian Neoplasms